Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neu

WALNUT CREEK, Calif. - March 21, 2022 - (Newswire.com) Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clin...

Related Keywords

Michigan ,United States ,David Reardon ,Tina Runk ,Joseph Rubinfeld ,Catherine Ivy Foundation ,Amgen ,Duke University School Of Medicine ,School Of Medicine ,Research Hospital ,Society For Neuro ,Clinical Research ,Clinical Oncology Research ,Dana Farber Cancer Institute ,Preston Robert Tisch Brain Tumor Center ,Company Neuro ,Vivacitas Oncology Inc ,Professor Of Medicine At Harvard Medical School ,University Of Michigan Hospital ,Pediatric Residency At Johns Hopkins University ,Advisory Board For Vivacitas Oncology Inc ,Tufts University School Of Medicine ,Harvard Medical School ,Clinical Director ,Neuro Oncology Advisory ,Medical Advisory Board ,Vivacitas Oncology ,Tufts University School ,Pediatric Residency ,Johns Hopkins University ,Duke University School ,Associate Deputy Director ,Rundles Award ,Clinical Operations ,Neuro Oncology Medical Advisory ,Executive Team ,Release Service ,Vivacitas Oncology Appoints Harvard Professor ,Neuro Oncology Medical Advisory Board ,